Lilly's Jaypirca reduces disease progression risk by 45%
Phase 3 BRUIN CLL-322 trial met primary endpoint with significant PFS improvement in previously treated CLL/SLL.
See the latest news and media coverage for Lilly. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global biopharmaceutical company
lilly.comLast updated
In short: Lilly reported positive results for its obesity and cancer pipelines, completed multiple acquisitions, and expanded Zepbound insurance coverage.
Phase 3 BRUIN CLL-322 trial met primary endpoint with significant PFS improvement in previously treated CLL/SLL.
The approval allows patients with moderate-to-severe atopic dermatitis to receive injections as few as six times per year without mandatory topicals.
Three Phase 3 ACHIEVE trials showed greater A1C reduction and weight loss versus oral semaglutide, dapagliflozin, and placebo; Lilly plans FDA submission by end of Q2 2026.
In ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo lost up to 14.4% of body weight and reduced waist circumference.
Pfizer, Amgen, and others look to compete with Novo Nordisk and Eli Lilly in the weight loss market.
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally...
Eli Lilly (NYSE:LLY) plans to reduce its previously announced €2.7b investment in Germany by half. T...
Eli Lilly and Company (NYSE:LLY) is one of the 12 Best Growth Stocks Trading in Oversold Territory. ...
Track Lilly and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lilly and other trending companies.